glp-1 shopping drug use cuts grocery spending by 6%, study finds How GLP-1 Drugs Are Cutting

The big advantage

GLP-1 receptor agonists are approved for use in children aged 10 and older with type 2 diabetes and obesity who have not achieved adequate glycemic control with metformin alone

In contrast, the liver, kidney, and adipose tissue showed no detectable human GLP1R signal (D, G, H)

Semaglutide may be especially familiar to patients because of its established role in obesity and diabetes care

A separate KFF analysis from March about Medicare Part D spending data from the Centers for Medicare & Medicaid Services found that gross Medicare spending on the three newest versions of GLP-1 diabetes medicines (Ozempic, Rybelsus and Mounjaro) that also have been approved for weight loss skyrocketed from $57 million in 2018 to $5.7 billion in 2022

doi:10.1111/j.1476-5381.2012.01971.x 11